{"id":"conventional-nsaa","safety":{"commonSideEffects":[{"rate":null,"effect":"Hot flashes"},{"rate":null,"effect":"Gynecomastia"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Gastrointestinal disturbance"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"NSAAs are non-selective antagonists that bind to the androgen receptor and inhibit its activation by androgens (testosterone and DHT), thereby suppressing androgen-dependent transcription in prostate cancer cells. This mechanism is distinct from selective AR antagonists and is used in androgen deprivation therapy for advanced prostate cancer. The conventional formulation represents earlier-generation AR antagonist technology compared to newer selective agents.","oneSentence":"Conventional NSAA (non-selective androgen antagonist) blocks androgen receptor signaling to suppress testosterone-driven prostate cancer growth.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:07:34.405Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced prostate cancer (metastatic castration-resistant or castration-sensitive)"}]},"trialDetails":[{"nctId":"NCT02446444","phase":"PHASE3","title":"Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Sydney","startDate":"2014-03","conditions":"Prostatic Neoplasms","enrollment":802},{"nctId":"NCT02446405","phase":"PHASE3","title":"Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Sydney","startDate":"2014-03","conditions":"Prostatic Neoplasms","enrollment":1125}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Conventional NSAA","genericName":"Conventional NSAA","companyName":"University of Sydney","companyId":"university-of-sydney","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Conventional NSAA (non-selective androgen antagonist) blocks androgen receptor signaling to suppress testosterone-driven prostate cancer growth. Used for Advanced prostate cancer (metastatic castration-resistant or castration-sensitive).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}